×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 8: Closing Remarks
Session Chair(s)
Robert A. Lionberger, PhD
Director, Office of Research and Standards, Office of Generic Drugs, CDER
FDA, United States
This session will serve to provide a summary of key points and highlights of the conference. Thoughts on future challenges and directions will be discussed.
Learning Objective : At the conclusion of this session, participants should be able to:
Summarize key takeaways from the conferenceDiscuss future challenges and directions for complex generic drug-device combination products
Have an account?